Dexchlorpheniramine
As of the edition of 20 October 2026, Dexchlorpheniramine is a small molecule: marketed, first approved in 1959 (ES); acts on HRH1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Polaramine
- First approved
- 1 January 1959 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- LABORATORIOS FARMACEUTICOS ROVI (ESPAGNE); 2 holders in all
- Registered trials
- 11, 2 stopped early
- Disease areas
- Immune system; Injuries; Skin and connective tissue; Chemically induced; Nervous system; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 8 | 0 | 1 | 2 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 11 |